caremark glp 1 coverage Employers find new option for workers' GLP-1 demand CVS Caremark sued over GLP-1

Receptor-mediated targeting: mannose receptor-targeted nanocarriers (e.g., liposomes and polymeric nanoparticles) decorated with URAT1-specific ligands demonstrate enhanced tubular accumulation, minimizing gastrointestinal adverse effects associated with systemic drug exposure ( 3.6.2 Spatiotemporally controlled sustained-release platforms Microsphere/liposome systems: PLGA- or lipid-encapsulated uricase formulations achieve weeks-to-months sustained release, reducing injection frequency and improving adherence in chronic regimens ( 2 composites) trigger drug release in acidic microenvironments (e.g., inflammation sites and crystal deposits), enhancing local efficacy (Mohamadi Bian and Moghadam, 2025

Similar mechanism to pregabalin with a longer track record

Thus, injections indirectly balance the mood and regulate appetite

doi:10.7150/ijbs.127096 This issue Cite Research Paper 1

The animal data is consistent

Daily target: 1.2-2.0g protein per kg body weight